Sol-Gel makes $27M derm drug delivery deal
This article was originally published in Scrip
Executive Summary
The private Israeli drug delivery company Sol-Gel Technologies has entered into a second development and licensing agreement with an undisclosed US pharmaceutical company. The deal covers the development and commercialisation of a "major" dermatological drug in the US and Canada, Sol-Gel says.